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Background: Leigh syndrome is a progressive neurodegenerative disorder, associated with primary or secondary
dysfunction of the mitochondrial oxidative phosphorylation. Despite the fact that Leigh syndrome is the most
common phenotype of mitochondrial disorders in children, longitudinal natural history data is missing. This study
was undertaken to assess the phenotypic and genotypic spectrum of patients with Leigh syndrome, characterise
the clinical course and identify predictors of survival in a large cohort of patients.
Methods: This is a retrospective study of patients with Leigh syndrome that have been followed at eight centers
specialising in mitochondrial diseases in Europe; Gothenburg, Rotterdam, Helsinki, Copenhagen, Stockholm, Brussels,
Bergen and Oulu.
Results: A total of 130 patients were included (78 males; 52 females), of whom 77 patients had identified
pathogenic mutations. The median age of disease onset was 7 months, with 80.8% of patients presenting by the
age of 2 years. The most common clinical features were abnormal motor findings, followed by abnormal ocular
findings. Epileptic seizures were reported in 40% of patients. Approximately 44% of patients experienced acute
exacerbations requiring hospitalisation during the previous year, mainly due to infections. The presence of
pathological signs at birth and a history of epileptic seizures were associated with higher occurrence of acute
exacerbations and/or relapses. Increased lactate in the cerebrospinal fluid was significantly correlated to a more
severe disease course, characterised by early onset before 6 months of age, acute exacerbations and/or relapses,
as well as brainstem involvement. 39% of patients had died by the age of 21 years, at a median age of 2.4 years.
Disease onset before 6 months of age, failure to thrive, brainstem lesions on neuroimaging and intensive care
treatment were significantly associated with poorer survival.
Conclusions: This is a multicenter study performed in a large cohort of patients with Leigh syndrome. Our data
help define the natural history of Leigh syndrome and identify novel predictors of disease severity and long-term
prognosis.
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Leigh syndrome or subacute necrotizing encephalo-
myelopathy, is a genetically heterogeneous, progressive
neurodegenerative disorder, that is usually associated
with defects involving mitochondrial oxidative phos-
phorylation (OXPHOS). This disorder primarily affects
infants and young children and is considered to be the
most common, distinct phenotype among OXPHOS dis-
orders in children with an estimated pre-school inci-
dence in western Sweden of 1 per 34,000 births [1].
Leigh syndrome was first described as a distinct neuro-
pathological entity with focal, bilaterally symmetrical, sub-
acute necrotic lesions extending from the thalamus to the
brainstem and the posterior columns of the spinal cord
[2]. Since then, the diagnosis of Leigh syndrome has been
based on symmetrical lesions in one or more areas of the
central nervous system, including the basal ganglia,
diencephalon, brainstem, cerebellum and spinal cord, on
either post mortem examination or on neuroimaging
[3,4]. Typically, the affected areas appear hypodense on
computed tomography (CT) and show hyperintense signal
on T2-weighted and hypointense signal on T1-weighted
magnetic resonance imaging (MRI) [5,6].
Onset of disease occurs typically between 3 and
12 months of age, with disease progression and death
within 2 years. Later onset and slower progression have
also been reported [3,4,7-9]. Clinical manifestations in-
clude motor delay, mental retardation and/or progressive
cognitive decline, hypotonia, dyskinesia, akinesia, ataxia,
dystonia and brainstem dysfunction, including respiratory
abnormalities, swallowing dysfunction, ophthalmological
manifestations and abnormal thermoregulation [3,10].
Leigh syndrome can be inherited as a mitochondrial
trait, as an autosomal recessive trait due to mutations in
nuclear genes encoding mitochondrial respiratory chain
complex subunits or complex assembly proteins [11]
and X-linked related to defects in pyruvate dehydro-
genase complex (PDHc) due to mutations in the PDHA1
gene (MIM# 300502) [12].
Leigh syndrome is a rare and heterogeneous disease ma-
king it difficult to obtain large cohorts of patients to study.
Although the clinical features of Leigh syndrome have been
described in published reviews, studies of longitudinal data
evaluating the natural history of the disease in a large
cohort of patients are lacking. Furthermore, the clinical re-
ports published so far have been based on small numbers
of patients and could not assess predictors of survival. The
Mitochondrial Clinical and Research Network (MCRN)
was established to facilitate research collaboration among
centers specialising in mitochondrial diseases. This project,
which aims to analyse the phenotypic and genotypic
spectrum of patients with Leigh syndrome, characterise the
clinical course and identify predictors of survival in a large
cohort of patients is the first joint study of this network.Materials and methods
Study design and population
The study was conducted as a retrospective analysis in
eight European centers specialising in mitochondrial dis-
eases that constitute the MCRN; Gothenburg, Rotterdam,
Helsinki, Copenhagen, Stockholm, Brussels, Bergen and
Oulu. We included patients with Leigh syndrome that
were diagnosed and followed at the participating centers
and that fulfilled both of the following inclusion criteria:
(i) clinical features compatible with Leigh syndrome, such
as psychomotor regression, dystonia, ataxia and/or brain-
stem dysfunction and (ii) MRI or CT or neuropathological
findings of Leigh syndrome, as follows: bilateral sym-
metrical lesions in the basal ganglia, and/or thalamus,
and/or brainstem. Patients were excluded from the study
if they had known syndromic mitochondrial phenotypes
other than Leigh syndrome.
Patient data were collected with the help of an
electronic-Case Report Form (e-CRF) that was com-
pleted by one designated investigator at each center
(Additional file 1: Table S1). Patient data included me-
dical history and survival status/date of last follow-up,
family history of neurological disorders, biochemical
findings, respiratory chain enzyme activities, muscle his-
tology and histochemistry, liver histology, brain neuro-
imaging, genetic findings and type of medical treatment
for Leigh syndrome. Preterm birth was defined as child-
birth occurring at less than 37 completed weeks of ges-
tation. The term ‘pathological signs at birth’ was defined
as any abnormal clinical and/or biochemical findings at
birth. Resistance to antiepileptic treatment was defined
as per the ILAE (International League Against Epilepsy)
definition [13]. A detailed list with the definitions of the
terms used in this study was provided as an attachment
in the e-CRF (Additional file 1: Table S1).
Each participating center received approval by the local
ethical committee Ethical Review Board at the University
of Gothenburg, as per the standing local regulatory re-
quirements, prior to the initiation of the study. Interim
monitoring procedures ensured the validity and integrity
of the collected data.
Statistical analysis
Statistical analysis was performed using the statistical
software package SAS v9.3. Due to the rarity of the
disease, no sample size calculation was performed in
advance and the study was not powered for specific sta-
tistical hypotheses. The statistical evaluations performed
were therefore mainly exploratory.
Kaplan-Meier analysis was used to estimate survival
outcomes. Differences in survival between groups were
evaluated with the Log rank test. Cox regression analysis
was performed to assess potential predictors of survival.
Wilcoxon-Mann–Whitney test was applied for the
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ween groups. Chi-square test and Fisher’s exact test
were used to test the association between categorical
variables. Multiple logistic regression analysis was per-
formed to further investigate the relationship between
binary response variables and potential predictors of
survival. Backward selection method was used to iden-
tify the best fitting model. All statistical tests were two-
sided and performed at a 0.05 significance level.
Results
Demographics and family history
A total of 130 patients with Leigh syndrome were enrolled
into the study, among whom 11 sibling pairs. There was a
slight male preponderance (78 males; 52 females). The
majority of the patients were European (73.1%), followed
by North-Africans (9.2%), Turks (3.8%), Kurds (2.3%) and
other ethnic groups (11.6%).
Parental consanguinity was present in 31 patients from
24 families. These were European (n = 7), North-African
(n = 7), Turkish (n = 4), Kurdish (n = 2), Pakistani (n = 2),
Lebanese (n = 1) and Iraqi (n = 1). The presence of mito-
chondrial disorders that did not fulfill the criteria of
Leigh syndrome was reported in siblings to three of our
patients with Leigh syndrome. Two of them, one with
neonatal encephalopathy and another with infantile car-
diomyopathy died early and autopsy was not performed.
The third refers to a sibling with clinical features and
course similar to his brother with Leigh syndrome, but
without the neuroimaging findings described in our in-
clusion criterion (ii).
Abnormal neurological findings were reported in three
mothers to children with Leigh syndrome, who carriedFigure 1 Median age of disease onset.the same mutations as their children -two with PDHc
deficiency and one with a pathogenic mutation in
MT-ATP6. One of these mothers suffered from poly-
neuropathy and ataxia, one mother had intentional
tremor, hyperreflexia of lower extremities, pes cavus and
difficulty in walking on heels, and the third mother had
both intentional and resting tremor.
Perinatal history
19 patients (14.6%) were born preterm. Most pregnancies
were uneventful (77.7%); the most common causes of
complicated pregnancy were preeclampsia and oligohy-
dramnios. 13 patients (10.0%) were born small for gesta-
tional age, while two patients presented intrauterine
growth restriction. Microcephaly was evident at birth in
six patients (4.6%). The median Apgar score at 1, 5 and
10 minutes was 9-9-10 (Q25: 7-9-9; Q75: 9-10-10). Nine
patients (6.9%) had respiratory difficulties at birth, of
whom eight required the following interventions: intu-
bation/ventilation (n = 4), oxygen by mask (n = 2) and
nasal CPAP (n = 2). 30 patients (23.1%) were reported to
have had pathological signs at birth, which apart from
respiratory difficulties, were hypotonia/floppiness (n = 7);
cardiac complications (n = 5); lactic acidosis (n = 4);
feeding/sucking difficulties (n = 3); dysmaturity (n = 2);
hypoglycaemia (n = 2); hyperbilirubinaemia (n = 2); hyper-
ammonaemia (n = 2); epileptic seizures (n = 1); hypertonia
(n = 1); contractures (n = 1), dysmorphic features (n = 1)
and increased plasma lactate with hyponatraemia (n = 1).
Disease onset and age at diagnostic testing
The median age of disease onset was 7 months, with
80.8% presenting by the age of 2 years (Figure 1). No
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onset (p = 0.775). Perinatal onset of disease was reported
in 17 patients (13.1%), while three patients were reported
to have intrauterine onset. One of these patients had car-
diomegaly and enlarged ventricles and germinolytic cysts
on prenatal ultrasound, as well as hypotonia and lactic
acidosis at birth; genetic etiology in this patient is still
unknown. The second patient with reported intrauterine
onset presented with contractures at birth, had an Apgar
score of 2-5-8 and respiratory complications necessitating
intubation. This patient was found to have SUCLA2 muta-
tions. The third patient had MT-ND3-associated Leigh
syndrome and an unknown perinatal history.
The patients with the latest age of onset -above the
90th percentile of the age-of-onset distribution of all
included patients- were 13 patients with age of onset
above 4.9 years. Their clinical presentations and disease
course are summarised in Table 1.
The patients underwent diagnostic testing for suspected
mitochondrial disease at a median age of 2.3 years (inter-
quartile range Q25-Q75: 0.8-6.3 years). The median
elapsed time from disease onset to diagnostic testing was
0.9 years (interquartile range Q25-Q75: 0.2-3.1 years).
Clinical features at onset
Leigh syndrome presented initially with abnormal motor
findings in the vast majority of patients (82.8%). Other
common features were abnormal ocular findings (25.0%),
feeding/sucking difficulties (14.1%), epileptic seizures
(13.3%) and failure to thrive (10.2%). The clinical features
at onset in relation to age at onset are depicted in
Figure 2.Table 1 Clinical presentation and disease course for the 13 pa
ID* Age of onset Clinical features at onset
84 5 y 1 m Hypotonia, mental retardation
66 4 y 11 m Dystonia, spasticity, hyperreflexia
94 8 y1 m Dystonia, hypertonia
95 18 y 8 m Gastrointestinal symptoms
15 6 y 7 m Hypotonia, ophthalmoplegia, fatigue
99 5 y 9 m Hypotonia, pos Babinski sign, ophthalmoplegia
103 6 y 5 m Dystonia, hypertonia, pos Babinski sign
114 7 y Dystonia
118 7 y Gastrointestinal symptoms
5 6 y Discoordination
124 10 y 5 m Hypo-hypertonia, dystonia, hypokinesia, dysarthria,
hyperreflexia, sucking dysfunction, bradyphrenia
127 8 y 2 m Hypertonia, hyperreflexia
25 19 y Spasticity, hemiparesis
*The ID numbers correspond to the ID numbers of the respective patients on Table
Y years; m months.Clinical features throughout the disease course
An overview of the patients’ clinical features is shown in
Table 2. The most common clinical features were abnor-
mal motor findings (99.2%), followed by abnormal ocular
findings (60.8%) (Table 2). More than half of the patients
had at least three affected organ systems during the
course of the disease. The three most frequently in-
volved systems were the motor, visual and gastrointes-
tinal system (Table 2).
Abnormal motor findings
Hypotonia was the most common motor finding (74.6%),
followed by abnormal tendon reflexes (47.7%) and dys-
tonia (44.6%) (Table 3). The most common presenting
motor features were hypotonia seen in 59.2%, abnor-
mal tendon reflexes (14.6%) and ataxia (12.3%) (Additional
file 2: Table S2). The relationship between motor findings
at onset and age at onset of Leigh syndrome are shown in
Figure 3. Dystonia, spasticity, hypertonia and choreoathe-
tosis were less frequent at onset but developed later in the
disease course (Additional file 2: Table S2).
Abnormal ocular findings
Abnormal ocular findings were present in 79 patients
(60.8%), the most prevalent being nystagmus (23.8%),
followed by strabismus (19.2%), visual impairment (16.2%),
optic atrophy (14.6%), ptosis (13.1%) and ophthalmoplegia
(12.3%).
Epileptic seizures
Epileptic seizures were reported in 51 patients (39.2%)
and were classified according to ILAE as follows:tients with the latest disease onset (above 4.9 years)
Exacerbations/relapses
requiring hospitalisation
Survival status Genetic
etiology
No Alive at 7 y 6 m Unknown
No Alive at 33 y C20orf7
No Alive at 18 y 10 m Unknown
Yes Died at 19 y 6 m Unknown
No Alive at 14 y 7 m MT-ATP6
Yes Alive at 33 y Unknown
No Alive at 8 y 6 m Unknown
No Lost to follow-up at 10 y Unknown
No Alive at 12 y 5 m Unknown
No Alive at 19 y 8 m MT-ND3
Yes Alive at 20 y 8 m Unknown
No Alive at 14 y Unknown
No Alive at 58 y MT-ATP6
4.
Figure 2 Overview of clinical features at onset.
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epileptic spasms (6.1%). In the subgroup of patients with
generalized seizures, myoclonic seizures were reported
in eight patients and absence epilepsy in three patients.
Resistance to antiepileptic treatment was reported in 16
patients.Table 2 Overview of clinical features throughout the
disease course
Frequency of affected organs/systems (n = 130) N %
Abnormal motor findings 129 99.2
Abnormal ocular findings 79 60.8
Feeding difficulties 59 45.4
Epileptic seizures 51 39.2
Respiratory dysfunction 49 37.7
Mental retardation 48 36.9
Sucking dysfunction 32 24.6
Hearing dysfunction 25 19.2
Cardiac dysfunction 23 17.7
Failure to thrive 21 16.2
Hepatic dysfunction 16 12.3
Microcephaly 15 11.5
Peripheral neuropathy 9 6.9
Renal dysfunction 7 5.4
Haematological dysfunction 2 1.5Respiratory dysfunction
Respiratory dysfunction was present in 37.7% with hyper-
ventilation and/or abnormal breathing pattern being the
most prevalent type (20.0%), followed by apnoea (16.1%),
obstructive or restrictive respiratory disease (13.8%) and
central hypoventilation (10.0%).Table 3 Abnormal motor findings
Type of abnormal motor findings (n = 130) N %
Hypotonia 97 74.6
Abnormal tendon reflexes§ 62 47.7
Dystonia 58 44.6
Babinski sign 55 42.3
Spasticity 47 36.2
Ataxia 45 34.6
Hypertonia 43 33.1
Muscle weakness 34 26.2
Other dyskinetic disorder^ 27 20.8
Paresis/palsy 26 20.0
Chorea/athetosis 25 19.2
Cavus feet 10 7.7
Myoclonus 9 6.9
Hypokinesia/bradykinesia 5 3.8
§Decreased or absent (n = 20) vs increased or clonic (n = 42).
^Tremor (n = 7); dysarthria (n = 4); dyscoordination (n = 3); cogwheel
phenomenon (n = 3); stereotypies (n = 3); opisthotonus (n = 2); hyperkinesia
(n = 2); dyspraxia (n = 1); jitteriness (n = 1); sleeping through phenomenon (n = 1).
Figure 3 Abnormal motor findings at onset in relation to age of onset.
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Cardiac dysfunction was present in 23 patients (17.7%),
with more than half having hypertrophic cardiomyo-
pathy (9.2%). Arrhythmia/conduction defects were re-
ported in five patients and dilated cardiomyopathy was
reported in two patients.
Other clinical features
59 patients manifested with feeding difficulties (45.4%)
sufficient to necessitate tube feeding (20.0%) and/or gas-
trostomy (33.0%). Mental retardation was found in 48
patients (36.9%). The severity of mental retardation was
classified as mild in 11 patients, moderate in 17, severe
in 15, profound in three and unspecified in two patients.
Hearing impairment was identified in 25 patients and
was sensorineural in 22, conductive in two and mixed in
one patient. Hepatic dysfunction was present in 16 pa-
tients (12.3%), with elevated liver transaminases in 12;
structural abnormalities defined by ultrasound or biopsy,
including liver steatosis and/or fibrosis in four; severe
liver failure in two and hepatomegaly in two patients.
Microcephaly was present in 15 patients (11.5%).
Other reported findings in descending order of fre-
quency were: gastro-intestinal dysfunction - including
constipation, diarrhea, dysphagia, vomiting, gastritis,
megacolon, intestinal paralysis (11.5%); dysarthria (11.5%);
hyperhidrosis/excessive sweating (9.2%); motor delay
(9.2%); peripheral neuropathy (6.9%); scoliosis (6.9%);
speech delay (6.1%); renal dysfunction (5.4%); sleepdisturbances (2.3%); hypothermia/hyperthermia (2.3%);
psychotic disorders (1.5%) and haematological dysfunction
in two patients, one of whom had b-thalassaemia minor
and another developed anaemia and thrombocytopenia
later in the disease course.
Biochemical, histological and genetic findings
The main biochemical, histological and genetic findings
are summarized in Table 4. 25% of the patients with avail-
able lactate values had a maximum lactate in blood and/or
cerebrospinal fluid (CSF) below or equal to 2.4 mmol/l,
which were considered to be normal. Of those patients
with normal lactate levels throughout the disease course,
10 patients had genetically verified disease (Table 4).
Elevated lactate in CSF (>2.4 mmol/l) was associated with
early onset of Leigh syndrome before 6 months of age
(p = 0.013), presence of hypotonia (p = 0.002), acute exac-
erbations and/or relapses (p = 0.014), brainstem lesions
on neuroimaging (p = 0.002) and absence of dystonia
(p = 0.011). No correlations were found between lactate
levels in CSF and a history of seizures, abnormal clinical
findings other than hypotonia, specific neuroimaging fin-
dings or the survival outcome.
Abnormal respiratory chain enzyme activity was found
in 70% of examined patients, with the most prevalent
being complex I deficiency. In 24 of 57 patients with ab-
normal histological findings in the muscle, at least one
of the following was found: cytochrome c oxidase defi-
ciency, succinate dehydrogenase deficiency, ragged red
Table 4 Lactate levels, respiratory chain enzyme activities, presence of muscle pathology and genetic findings in 130 patients with Leigh syndrome
ID Age of onset B-lactate CSF-lactate Complex deficiency Muscle pathology Genetic etiology ID Age of onset B-lactate CSF-lactate Complex
deficiency
Muscle
pathology
Genetic
etiology
1 3 m 4.0 4.7 CI - MT -ND1 66 4 y 11 m 1.9 NA CI + C20orf7
2 2 y 6 m 3.0 3.9 CI + MT -ND1 67 4 y 1 m 4.6 NA CI + C20orf7
3 IU 2.6 2.5 CI +§ MT-ND3 68 1 y NA NA CIV - C12orf65
4 4 m 8.0 6.4 CI - MT-ND3 69 Perinatal 10.2 NA CI, CII + NDUFA9
5 6 y 1.5 2.5 - - MT -ND3 70 2 m 4.9 2.4 CI + NDUFA12
6 1 y 7.7 NA CI, CIV - MT -ND3-4 71 3 m 5.7 NA CI, CIII - NDUFAF2
7 11 m 10.4 2.2 CI, CV + MT -ND5 72 4 m NA NA CI - NDUFAF2
8 Perinatal 22.9 NA CI, CIII, CIV + MT-ND5 73 6 m 4.1 NA CI + NDUFV2
9 8 m 1.6 3.7 CI - MT -ND5 74 5 m 15.0 NA CI - NDUFV2
10 1 y 4 m 5.0 3.2 CI + MT-ND6 75 3 y 3 m 1.6 NA CI, CIII + NDUFS7
11 1 y 9 m 3.2 4.6 - + MT-ATP6 76 3 m 10.2 4.7 CI - NDFUS4
12 11 m 2.1 NA NA NA MT-ATP6 77 9 m 3.6 2.0 CIII - BCS1L
13 5 m 4.4 NA NA NA MT-ATP6 78 7 m 4.2 4.0 CI + Unknown
14 Perinatal 8.5 5.9 CV + MT-ATP6 79 7 m 1.5 1.5 CII - Unknown
15 6 y 7 m 1.5 2.4 CV + MT-ATP6 80 6 m 7.0 3.2 CI + Unknown
16 1 y 2 m 2.1 2.7 CI-IV - MT-ATP6 81 2 y 1.0 1.9 - - Unknown
17 4 m 4.7 5.2 CI-IV + MT-ATP6 82 1 y 3 m 4.4 NA - + Unknown
18 2 y 3 m 1.5 2.7 - +§ MT-ATP6 83 Perinatal 2.8 2.0 CIV + Unknown
19 6 m 3.1 3.3 - - MT-ATP6 84 5 y 1 m 1.1 6.1 NA NA Unknown
20 4 m 2.4 3.3 - - MT-ATP6 85 1 y 5 m 2.7 2.3 - + Unknown
21 5 m 5.4 5.7 CI-IV - MT-ATP6 86 1 y 4 m 1.2 NA - + Unknown
22 6 m 6.2 6.2 CI, CIII, CIV, CV - MT-ATP6 87 Perinatal 7.5 12.9 CI, CIII + Unknown
23 3 m 5.5 5.8 CV - MT-ATP6 88 1 y 2 m 5.5 3.0 CI, CIV + Unknown
24 3 m 6.4 8.1 - + MT-ATP6 89 7 m 4.4 5.9 CI, CII + Unknown
25 19 y 1.2 NA NA NA MT-ATP6 90 2 m 5.6 2.1 CI-III + Unknown
26 1 y 6 m 0.8 2.1 CV + MT-ATP6 91 Perinatal 17.0 NA - - Unknown
27 8 m 8.9 2.8 CI, CIV + MT-TW 92 Perinatal 6.7 3.7 CI - Unknown
28 2 y 14.8 4.0 CI, CIV + MT-TL1;MT-TE 93 8 m NA NA CIV NA Unknown
29 1 y 4 m 3.4 4.0 CIV + SURF1 94 8 y 1 m NA NA CI - Unknown
30 Perinatal 5.6 6.0 CIV + SURF1 95 18 y 8 m 2.4 3.1 - - Unknown
31 1 y 3.5 3.3 CIV + SURF1 96 1 y 1 m NA NA - - Unknown
32 5 m 7.8 6.0 CIV + SURF1 97 3 m 3.3 NA CIV + Unknown
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Table 4 Lactate levels, respiratory chain enzyme activities, presence of muscle pathology and genetic findings in 130 patients with Leigh syndrome (Continued)
33 1 y 2.6 NA CIV NA SURF1 98 7 m 5.7 3.9 CI-IV + Unknown
34 2 m NA NA CIV - SURF1 99 5 y 9 m 2.5 3.5 CI + Unknown
35 8 m NA NA CIV - SURF1 100 1 y 12.4 1.3 - - Unknown
36 5 m 3.3 3.6 CIV + SURF1 101 Perinatal 8.4 6.3 CI, CIV + Unknown
37 1 m 3.0 3.2 NA NA SLC19A3 102 8 m 0.8 1.0 - - Unknown
38 1 m NA NA NA NA SLC19A3 103 6 y 5 m 3.1 1.8 CI NA Unknown
39 Perinatal 2.1 NA NA NA SLC19A3 104 IU 11.1 NA NA NA NA
40 6 m 3.1 NA - + SLC19A3 105 4 m 4.4 3.7 - - Unknown
41 1 m 4.4 NA - - SLC19A3 106 2 y 2.9 17.0 CI, CV + Unknown
42 1 m 3.4 2.1 CIV NA SLC19A3 107 Perinatal 4.8 5.5 CI - NA
43 1 m 3.8 NA NA NA SLC19A3 108 6 m 1.6 2.7 NA NA NA
44 2 y 7 m 3.3 1.2 - - SLC19A3 109 3 y 2.8 1.7 CI-IV + Unknown
45 3 m 2.0 1.7 - - SLC19A3 110 6 m 4.7 3.1 CI-IV +§ Unknown
46 5 m 2.1 NA - + SUCLA2 111 7 m 2.1 4.1 NA NA NA
47 1 m 3.0 3.3 NA NA SUCLA2 112 7 m 2.3 4.1 CI-IV + Unknown
48 3 m 5.9 2.9 NA NA SUCLA2 113 Perinatal 7.9 2.8 CI, CIV + Unknown
49 5 m 1.4 NA NA NA SUCLA2 114 7 y 2.4 1.4 - - Unknown
50 2 m NA 6.3 NA NA SUCLA2 115 1 m 0.8 4.4 - - Unknown
51 3 m NA NA NA NA SUCLA2 116 3 y 8 m 5.7 5.0 - + Unknown
52 Perinatal 4.9 NA CI, CIII, CIV NA SUCLA2 117 4 y 2.1 1.8 - - Unknown
53 Perinatal 5.6 3.1 CI, CIV + SUCLA2 118 7 y 2.3 1.3 CI + Unknown
54 IU 4.3 NA CIV - SUCLA2 119 11 m 2.6 NA - - Unknown
55 5 m 4.5 2.8 CI, CIV - SUCLA2 120 4 m 3.9 1.2 - + Unknown
56 7 m 5.0 2.1 CI, CIV + SUCLG1 121 1 y 8 m 4.2 3.1 CI + Unknown
57 3 m 5.1 4.7 CI-IV NA SUCLG1 122 1 y 1 m 4.3 NA - - Unknown
58 4 y 7 m 3.3 3.7 - - PDHA1 123 Perinatal NA NA NA NA Unknown
59 10 m 5.0 NA - - PDHA1 124 10 y 5 m 3.7 NA CI, CIII + Unknown
60 1 y 2 m 3.4 NA NA NA PDHA1 125 5 m 1.3 2.8 CI + NA
61 8 m 6.2 6.2 CII - PDHA1 126 2 y 11 m NA NA - + Unknown
62 7 m NA NA NA NA PDHA1 127 8 y 2 m 4.2 NA CI - NA
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Table 4 Lactate levels, respiratory chain enzyme activities, presence of muscle pathology and genetic findings in 130 patients with Leigh syndrome (Continued)
63 8 m 5.6 3.0 - + SERAC1 128 4 y 3 m 1.5 NA CI, CIII + NA
64 Perinatal 3.8 9.1 CII, CIII - SERAC1 129 1 y 9 m 3.9 1.5 CI - Unknown
65 Perinatal 2.6 3.0 - - SERAC1 130 6 m 8.3 5.4 NA NA NA
B Blood; CSF Cerebrospinal fluid; NA Not applicable; CI Complex I deficiency; CII Complex II deficiency, CIII Complex III deficiency, CIV Complex IV deficiency; CV Complex V deficiency; CI-III Complex I to complex III
deficiency; CI-IV Complex I to complex IV deficiency; y year(s); m month(s); IU intrauterine; §on electron microscopy.
Numbers in ‘bold’ represent the patient ID numbers.
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Genetic etiology was confirmed in 77 patients (59.2%) of
which nuclear DNA mutations were much more com-
mon than mitochondrial DNA mutations (37.7% and
21.5% respectively) (Table 4).Acute exacerbations
The study population was followed up for a median
time of 9.6 years from disease onset. In total, 56.9% of
patients experienced at least one acute exacerbation
requiring hospitalisation during their disease course,
43.8% during the previous year. Of these, one fourth
had at least three exacerbations during the previous
year. Intensive care was required in 39.2% of hospi-
talized patients. The main cause of acute exacerbation
was infection (60.8%); other causes included respiratory
complications (13.5%), stroke-like episodes (4.0%) and
poor nutrition or dehydration (4.0%).Survival status
53 patients were alive at the time of data analysis
(40.8%), 51 were dead (39.2%) and 26 (20.0%) were lost
to follow-up. Median age at death was 2.4 years (range:
1 month – 21 years). The elapsed median time from
disease onset to death was 1.8 years. Main causes of
death were respiratory complications (51.0%), progres-
sion of Leigh syndrome (17.6%) or infection (17.6%).Figure 4 Kaplan-Meier survival curve.The survival analysis for the study population is shown
in Figure 4.Factors associated with acute exacerbations and/or
relapses
The following factors were analysed using a univariate
analysis: gender, age at onset below versus above 6 months,
pathological signs at birth, complex IV deficiency, gene-
tically verified disease, mitochondrial DNA mutations,
nuclear mutations, presence of specific genetic defects (i.e.
SUCLA2; SLC19A3; SURF1; MT-ATP6; mitochondrial
NADH dehydrogenase subunits 1 to 6), muscle pathology,
brainstem dysfunction on neuroimaging, basal ganglia
dysfunction alone on neuroimaging and presence of any
of the following clinical features - dystonia, ataxia, epilep-
tic seizures, cardiac dysfunction, failure to thrive, hepatic
dysfunction. Of these, the presence of pathological signs
at birth and a history of epileptic seizures showed a sig-
nificant association with higher occurrence of acute exac-
erbations and/or relapses. The presence of basal ganglia
dysfunction alone on neuroimaging was significantly asso-
ciated with lower occurrence of acute exacerbations and/
or relapses.
We then tested these factors using multiple logistic
regression analysis. This confirmed that the presence of
pathological signs at birth and a history of epileptic
seizures are the two factors significantly associated with
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(p = 0.0081 and p = 0.0005, respectively).
Factors associated with survival
The same factors were analysed for their association with
patient survival, together with the occurrence of acute ex-
acerbations/relapses and requirement of intensive care.
The univariate analysis showed that the following were as-
sociated with poorer survival: age of onset below or equal
to 6 months, history of epileptic seizures, failure to thrive,
hospitalisation in intensive care unit, genetically verified
disease, SLC19A3 mutations, mt.8993 T > G mutation,
SURF1 mutations and brainstem lesions on neuroimaging.
The multivariate analysis confirmed that age of onset
before 6 months, failure to thrive, brainstem lesions on
neuroimaging and requirement of intensive care are pre-
dictors of poorer survival (Figures 5, 6, 7 and 8, Additional
file 3: Figure S1).
Discussion
We present natural history data on a unique cohort of
130 patients with Leigh syndrome. Our data help define
the natural history of Leigh syndrome and identify novel
factors that predict outcome and long-term prognosis.
Our findings are essential in order to provide optimal
management and monitor the effect of future therapies.
Leigh syndrome is traditionally considered to be a dis-
ease of infancy and early childhood with disease onset be-
fore the age of 2 years [4,14-16]. In our study, we choseFigure 5 Kaplan-Meier survival curve for disease onset before versusnot to use an age-of-onset criterion, but the clinical and
pathological diagnostic criteria for Leigh syndrome. This
was done to better understand the age-of-onset distribu-
tion of Leigh syndrome, to identify the frequency of late-
onset Leigh syndrome and differences between early and
late-onset Leigh syndrome.
Prenatal expression of mitochondrial disease has been
described with abnormal brain neuroimaging performed
in utero and associated clinical features emerging at
birth or during early postnatal life [17-19]. There are few
reports associating abnormal intrauterine findings with
postnatal development of Leigh syndrome [17,20]. The
patient with Leigh syndrome reported by Kumakura
et al., had intrauterine findings of oligohydramnios and
intrauterine growth restriction in addition to abnormal
brain neuroimaging [20]. We report two patients with
abnormal intrauterine findings associated with perinatal
development of Leigh syndrome. In total, pathological
signs at birth were reported in 23% of our patients.
However, only half of these patients were reported to
have perinatal onset of Leigh syndrome. This figure is in
accordance with previous reports that range from 15%
[21] to 32% [15]. We found a positive correlation bet-
ween the presence of pathological signs at birth and the
occurrence of acute exacerbations during the disease
course. The relatively high incidence of pathological
signs at birth, even if not fully expressing Leigh syn-
drome, suggests that an ongoing energy failure linked to
mitochondrial dysfunction may already have started inafter 6 months of age.
Figure 6 Kaplan-Meier survival curve for those patients with versus without history of failure to thrive.
Figure 7 Kaplan-Meier survival curve for those patients with versus without history of treatment in intensive care unit (ICU).
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Figure 8 Kaplan-Meier survival curve for those patients with versus without brainstem lesions on neuroimaging.
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more susceptible to external stress factors, such as infec-
tion, poor nutrition and dehydration, leading to acute
exacerbations later in the disease course. The factors
that regulate the expression time –from in utero to
adulthood- of this mitochondrial energy failure remain
to be understood.
Late-onset Leigh syndrome, i.e. presentation in late
childhood, adolescence or adulthood, is considered rare.
In our study, however, 19.2% of the patients had onset
after 2 years of age, with the latest onset (10%) after
4.9 years of age. Late-onset Leigh syndrome has been as-
sociated with predominant extrapyramidal features, slow
progression and acute deterioration, but atypical presen-
tations have also been described [9]. In their review of
late-onset Leigh syndrome, McKelvie et al., presented 13
patients with onset of Leigh syndrome between 17 and
74 years [22]. These patients had highly variable clinical
features, the most prominent being ataxia, spasticity,
dysarthria and abnormal ocular findings. Prognosis was
observed to be poor with 10 of 13 patients dying within
2 weeks to 6 years from disease onset [22]. In contrast,
of the 13 patients with the latest onset presented in our
study (10%), all but two patients were alive. There was a
high prevalence of dystonia and ataxia in this subgroup
of patients, suggesting that such involvement might be
age dependent. The heterogeneity of the phenotypic
spectrum and of the disease course of Leigh syndrome
makes it difficult to define an age cut-off in order toidentify late-onset Leigh syndrome. However, based on
the age-of-onset distribution of our patients, we propose
the age of 2 years as a cut-off to distinguish between
early versus late-onset Leigh syndrome.
While Leigh syndrome is not primarily a disease
affecting the cerebral cortex, 40% of our patients de-
veloped epileptic seizures. The reported prevalence of
seizures in Leigh syndrome ranges from 40% to 79%
[4,14,15,23]. In addition, we found a significantly higher
occurrence of acute exacerbations and/or relapses in pa-
tients with a history of seizures. However, seizures were
the cause of exacerbations and/or relapses in only three
patients. The relapse occurrence was attributed to infec-
tions in the vast majority of our patients with history of
seizures. Our findings suggest that patients with Leigh
syndrome and a history of seizures are at risk of acute
exacerbations and have increased need for hospitalisa-
tion when infected.
The survival rate in Leigh syndrome is generally con-
sidered to be poor. Rahman et al., reported a survival of
20% by the age of 20 years, with death typically occur-
ring by age 2 to 3 years [4]. In the study by Lee et al.,
eight of 14 patients (57%) had died by the age of 16 years,
seven of whom by the age of 18 months [14]. Poor prog-
nosis was reported by Naess et al.; 68% of patients died
by the age of 15 years, 40% of patients at preschool age
[15]. Our study population was found to have a better
survival rate, with 41% of patients being alive at a
median follow-up of 11.4 years from birth (range: 0.1 –
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by the age of 21 years, an early mortality was found at a
median age of 2.4 years.
The natural history of Leigh syndrome has been
described for the subgroups of SURF1 deficiency, cyto-
chrome c oxidase deficiency due to LRPPRC mutations
and complex I deficiency [24-26]. In particular, SURF1-
deficient Leigh syndrome was found to have a more fa-
vorable survival outcome compared to Leigh syndrome
associated with complex I-deficiency or LRPPRC muta-
tions [24].
Predictors of survival in Leigh syndrome have not
previously been assessed, probably due to the small
numbers of patients per study. We found disease onset
before 6 months of age, failure to thrive, brainstem
lesions on neuroimaging and intensive care treatment to
be associated with poorer survival. Poor survival in pa-
tients with onset before 6 months of age has been pre-
viously reported, not only in Leigh syndrome [15] but in
mitochondrial disorders in general [1]. The effect of
brainstem dysfunction on patient outcome has been
studied in 130 patients with complex I deficiency, half of
them with the diagnosis of Leigh syndrome, and no cor-
relation was found [26]. In our study, respiratory com-
plications were found to be the leading cause of death,
with half of our patients dying of this complication. In
view of the significant correlation between brainstem
lesions on neuroimaging and poor survival, we believe
that brainstem involvement may also be responsible for
the respiratory complications seen in patients with Leigh
syndrome. Patients treated in intensive care unit appear
to have a higher risk of death. As respiratory complica-
tions and disease progression accounted for the majority
of deaths, we believe that it is the disease severity with
signs of progressive brainstem involvement related to
the respiratory insufficiency, of the patients admitted
to intensive care unit that mainly leads to increased
mortality.
Cardiomyopathy has been associated with poor sur-
vival in mitochondrial diseases [27]. In a study of 101
patients with all types of mitochondrial disorders, car-
diomyopathy was found in 17% of patients and was asso-
ciated with increased mortality [27]. Cardiac dysfunction
was found in 18% of our patients. This is almost as high
as that reported by Lee et al. [14], but higher than in
other studies [4,15,23]. Among the 23 patients with car-
diac dysfunction included in our study, 11 patients had
died by the time of data capturing, 9 patients were alive
and 3 patients were lost to follow-up. Cardiac dysfunc-
tion was not associated with poor survival or increased
risk of disease relapse in our patients.
Rahman et al., included the presence of increased lactate
in either blood or CSF among the diagnostic criteria for
Leigh syndrome [4], a criterion that has been questioned[15]. In our study, 25% of the patients with available lac-
tate values either in blood or CSF had normal levels
throughout the disease course. Of these, 10 patients had
genetically verified disease. We conclude, therefore, that
the clinical and pathological inclusion criteria used in our
study, which do not include any laboratory parameters,
are more appropriate as diagnostic criteria for Leigh
syndrome. Increased lactate in CSF was significantly cor-
related to a more severe disease course in our patients,
characterised by early onset before 6 months of age, acute
exacerbations and/or relapses, as well as brainstem in-
volvement. We believe, therefore that the presence of ab-
normal lactate in CSF may be used as a prognostic factor
of disease severity in Leigh syndrome.
A limitation of the present paper is that all participa-
ting centers are located in Northern and Western
Europe, and as a result, the majority of patients have a
specific genetic background which may determine dif-
ferences in other regions of the world.
Leigh syndrome should be differentiated from other
diseases associated with degeneration of the basal ganglia
in the paediatric population, such as carbon monoxide
intoxication, infantile bilateral striatal necrosis (IBSN),
Wilson’s disease, juvenile Huntington’s chorea, neuro-
generation with brain iron accumulation, familial degene-
ration of the striatum and GAMT (guanidinoacetate
methyltransferase) deficiency. These diseases can generally
be ruled out on the basis of laboratory tests, history of
exposure to toxins and family history. IBSN includes a
heterogeneous group of disorders, characterised by bila-
teral symmetrical degeneration predominantly of the
caudate nuclei and the putamen. Etiologically, IBSN has
been attributed to infectious and autoimmune processes,
while a mitochondrial dysfunction has also been suggested
in familial cases [28]. Non-familial IBSN differs from Leigh
syndrome in the absence of a chronic progressive course
[28,29]. In view of the fact that familial IBSN shows a
phenotypic spectrum that overlaps with that of Leigh syn-
drome with lesions restricted to the striatum, we suggest
that primary or secondary defects of the mitochondrial
OXPHOS should be considered.
At least 3.1 years elapsed from disease onset to diagnos-
tic testing for suspected mitochondrial disease in 25% of
our patients with Leigh syndrome. A delay in diagnosis is
common in mitochondrial diseases. In a case series by Lee
et al., on 21 patients with SURF1-associated Leigh syn-
drome, the median age at the time of molecular diagnosis
was 4.1 years with a range from 1.2 to 22.0 years [30]. A
better understanding of the phenotypic spectrum and
natural history of Leigh syndrome can lead to earlier
diagnosis and improved counseling to the family, inclu-
ding prenatal counseling. The identification of genotype-
phenotype and genotype-neuroimaging correlations is
essential and it is the next step of our research work.
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Leigh syndrome is a genetically heterogeneous disorder
characterised by a vast spectrum of phenotypes and a vari-
able disease course. We present longitudinal natural his-
tory data from a unique cohort of 130 patients with Leigh
syndrome. We discuss the diagnostic criteria of Leigh syn-
drome and propose novel predictors of disease severity
and long-term prognosis. Our findings are essential in
order to provide optimal management and monitor the
effect of future therapies.
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